Billions boost next-generation weapons against SARS-CoV-2.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 37883560.
- Also identified by DOI 10.1126/science.adl5523.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
U.S. government project bets big on intranasal vaccines and monoclonal antibodies, but omits more ambitious approaches.
Medical subject headings
- Antibodies, Monoclonal
- COVID-19
- SARS-CoV-2
- COVID-19 Vaccines